Key facts
- Greenoaks and Sequoia Capital co-led the $5 billion Series C round.
- Andreessen Horowitz joined as a new investor alongside existing backers GV, Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
- Isomorphic Labs said its program has yielded positive preclinical results in oncology and immunology.
- The company has struck deals with Eli Lilly, Novartis and Johnson & Johnson.
- The round follows a $2.1 billion Series B in May 2026 and is the first since Demis Hassabis left as head of DeepMind.
Isomorphic Labs, the AI drug-discovery platform spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C funding round, the company said in a report published on November 17, 2026. The round was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating.
All of the company's existing backers also invested, including Alphabet's venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. The new funding follows a $2.1 billion Series B round in May 2026 and will be used to continue developing its drug-design engine and to move into more types of medicine.
Isomorphic Labs builds an AI drug-design engine that uses simulation AI models exploring various areas of chemistry to help design drugs. The company, whose work builds on DeepMind's AlphaFold protein-folding AI model, said its program has yielded "positive preclinical results" in oncology and immunology. It has struck deals with Eli Lilly, Novartis, and Johnson & Johnson.
The Series C is Isomorphic's first fundraise since founder and CEO Demis Hassabis left his position as head of DeepMind to focus on drug discovery, moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab's work on AlphaFold, a system that predicts the 3D structure of proteins from their genetic sequence.
Isomorphic did not disclose its new valuation. Bloomberg reported earlier in November 2026 that the lab was looking to raise funding at a $50 billion valuation.
